- For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
OR
OR
OR
OR
OR
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
Cisplatin Carboplatin Paclitaxel Docetaxel Vinorelbine GemzarR (gemcitabine) Etoposide Irinotecan Vinblastine AvastinR (bevacizumab) AlimtaR (pemetrexed) | Various doses | Number of cycles vary |
Gilotrif (afatinib)* | EGFR positive disease: 40 mg PO QD | 40 mg |
Tarceva (erlotinib) | EGFR positive disease: 150 mg PO QD | 150 mg |
Zykadia (ceritinib)* | ALK positive NSCLC: 750 mg PO QD | 750 mg |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Xalkori | 250 mg PO BID May require reduction to 200 mg BID or 250 mg QD | Length of benefit or until disease progression |